Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by fossi_2002on Dec 30, 2022 11:08am
113 Views
Post# 35196966

RE:RE:RE:RE:RE:Volume 131,400 in Canada

RE:RE:RE:RE:RE:Volume 131,400 in Canada
Again today RBC is the seller, on the other side Anonymus (that's me in this case) is the buyer. This is certainly about year-end prices.
The positive future possibilities have been mentioned here several times by Proph and Lauren.
On the other hand, it has to be seen that the overall market might remain negative and Ceapro could show lower profits due to higher costs for research and investments.
If Avenanthramide goes wrong (which I don't think it will) and profits fall at the same time, further share price declines are likely.
Another quick comment for HOPE because you always whine about sales volume. As I myself was a trader on the stock exchange and have bought Ceapro for clients from time to time in recent months, I can tell you that it is quite common on the stock exchange to apply purchases and sales of a brokerage house, i.e. 100,000 shares can be traded without them even being displayed.

<< Previous
Bullboard Posts
Next >>